Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institutionM. Azoulay, Bassam Abdulkarim, Fabiano Santos et al.|Journal of Neuro-Oncology|2017Cited by 83
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Byoung Chul Cho et al.|Annals of Oncology|2024Cited by 81
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre studyAntoine Desîlets, Arielle Elkrief, Nicolas Marcoux et al.|European Journal of Cancer|2020Cited by 78
A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With GlioblastomaGeorge Shenouda, Bassam Abdulkarim, Luís Souhami et al.|International Journal of Radiation Oncology*Biology*Physics|2016Cited by 58
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institutionM. Azoulay, Bassam Abdulkarim, Fabiano Santos et al.|Radiation Oncology|2015Cited by 21